Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA

Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. R...

Full description

Saved in:
Bibliographic Details
Published in:Current bladder dysfunction reports 2018-06, Vol.13 (2), p.25-30
Main Authors: Kirby, Anna C., Kellogg, Elizabeth S.
Format: Article
Language:English
Subjects:
Geriatrics/Gerontology
Gynecology
Medicine
Medicine & Public Health
Overactive Bladder (U Lee and S Adelstein
Section Editors
Topical Collection on Overactive Bladder
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications. Summary Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.
ISSN:1931-7212
1931-7220
DOI:10.1007/s11884-018-0462-7